van Oosterom A T, Schrijvers D, Schriivers D [corrected to Schrijvers D ]
Department of Oncology, University Hospital, Antwerp, Edegem, Belgium.
Anticancer Drugs. 1995 Jun;6(3):356-68. doi: 10.1097/00001813-199506000-00002.
Docetaxel, a promising inhibitor of microtubule depolymerization has shown significant anti-cancer activity during phase I and early phase II trials. The recommended dosage for phase II trials is 100 mg/m2 every 3 weeks which provides optimal activity with tolerable adverse effects. Docetaxel has shown high single agent activity including use as first- or second-line therapy and in anthracycline refractory breast cancer patients. Results have been comparable to that of established treatments for breast cancer. In addition, docetaxel has shown significant activity in non-small cell lung cancer and a range of other tumors, but no activity in renal or colo-rectal tumors. At present it is undergoing further evaluation in combination therapy. The safety profile of docetaxel is well defined. Major adverse effects include hypersensitivity reactions, fluid retention and neutropenia. Peripheral neuropathy is not a significant adverse effect. The aims of phase II trials with regard to counteracting side-effects are therefore 2-fold: firstly, to evaluate the use of premedication with corticosteroids and antihistamines as a means of counteracting hypersensitivity reactions and fluid retention; secondly, to determine whether granulocyte colony stimulating factor may be useful for attenuating neutropenia.
多西他赛是一种有前景的微管解聚抑制剂，在I期和II期早期试验中已显示出显著的抗癌活性。II期试验的推荐剂量为每3周100mg/m²，该剂量可提供最佳活性且不良反应可耐受。多西他赛已显示出较高的单药活性，包括用作一线或二线治疗以及用于蒽环类难治性乳腺癌患者。其结果与既定的乳腺癌治疗方法相当。此外，多西他赛在非小细胞肺癌和一系列其他肿瘤中已显示出显著活性，但在肾肿瘤或结直肠癌中无活性。目前它正在联合治疗中接受进一步评估。多西他赛的安全性概况已明确。主要不良反应包括过敏反应、液体潴留和中性粒细胞减少。周围神经病变不是显著的不良反应。因此，II期试验针对副作用的目标有两个：第一，评估使用皮质类固醇和抗组胺药进行预处理作为对抗过敏反应和液体潴留的手段；第二，确定粒细胞集落刺激因子是否可用于减轻中性粒细胞减少。
